Last Publications
- Castañeda-Heredia A, Maite Gorostegui Obanos, Miralles SL, ALICIA CHAMIZO BREMER, Patiño SC, Flores MA, Garraus-Oneca M, Lazaro JJ, Santa-María López V, Varo A, Muñoz JP and Mora J How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain. ESMO Open . 7(2): 100462-100462.
- Inarejos E, Navarro OM, Navallas M, Enrique Ladera Gonzalez, Torner-Rubies F, Suñol M, Garraus-Oneca M, March JC and Ignacio Barber Martínez de la Torre Multiparametric MRI evaluation of bone sarcomas in children. Insights into Imaging . 13(1): 33-33.
- Mora J, Castañeda-Heredia A, Gorostegui M, Santa-María V, Garraus-Oneca M, Muñoz JP, Varo A, Pérez-Jaume S and Mañe S Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission. PEDIATRIC BLOOD & CANCER . 68(10): 29121.
News
-
Survival rate of high-risk neuroblastoma patients treated with next-generation immunotherapy at SJD Barcelona Children's Hospital
Researchers of SJD Barcelona Children's Hospital and of Institut de Recerca Sant Joan de Déu (IRSJD) have published the results of treatment with the humanised anti-GD2 antibody Naxitamab (DanyelzaR) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF; LeukineR) in high-risk neuroblastoma patients.